Neubauer David N
Johns Hopkins Sleep Disorders Center, 4940 Eastern Ave, Box 151, Baltimore, MD 21224, USA.
Am J Manag Care. 2009 Feb;15 Suppl:S24-32.
Insomnia occurs predominantly in conjunction with a medical or psychiatric illness. New thinking regarding the treatment of comorbid insomnia has moved the field away from practices that called for treating the comorbid condition to resolve the coexisting insomnia to one in which the insomnia is treated as a separate condition. Although 10 medications currently are approved by the US Food and Drug Administration for the treatment of insomnia, only 2, eszopiclone and zolpidem, have been evaluated for efficacy in patients with chronic comorbid insomnia. Studies suggest clear benefits in comorbid insomnia. Nonpharmacologic treatments, such as cognitive behavioral therapy, sleep hygiene, and relaxation training, have also been investigated for comorbid insomnia, with studies suggesting these approaches may be effective either alone or in conjunction with medications. While behavioral issues should be optimized, clinicians need to customize treatments for patients with comorbid insomnia based on coexisting medical and psychiatric morbidities, age, medical history, current medications, and lifestyle issues.
失眠主要与内科疾病或精神疾病同时发生。关于共病性失眠治疗的新观念已使该领域从过去那种通过治疗共病来解决并存的失眠的做法,转向将失眠作为一种单独病症进行治疗的做法。尽管目前有10种药物已获美国食品药品监督管理局批准用于治疗失眠,但仅有艾司佐匹克隆和唑吡坦这2种药物针对慢性共病性失眠患者的疗效进行了评估。研究表明,共病性失眠患者明显受益。非药物治疗方法,如认知行为疗法、睡眠卫生和放松训练,也已针对共病性失眠进行了研究,研究表明这些方法单独使用或与药物联合使用可能有效。虽然行为问题应得到优化,但临床医生需要根据并存的内科和精神疾病、年龄、病史、当前用药情况以及生活方式问题,为共病性失眠患者定制治疗方案。